acetazolamide has been researched along with Ventricular Dysfunction, Left in 2 studies
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acetazolamide inhibits proximal tubular sodium reabsorption and improved decongestion in the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial." | 9.69 | Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial. ( Augusto, SN; Damman, K; Dauw, J; Dupont, M; Filippatos, G; Martens, P; Mebazaa, A; Meekers, E; Mullens, W; Nijst, P; Ruschitzka, F; Tang, WHW; Ter Maaten, JM; Verbrugge, FH, 2023) |
| "Acetazolamide inhibits proximal tubular sodium reabsorption and improved decongestion in the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial." | 5.69 | Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial. ( Augusto, SN; Damman, K; Dauw, J; Dupont, M; Filippatos, G; Martens, P; Mebazaa, A; Meekers, E; Mullens, W; Nijst, P; Ruschitzka, F; Tang, WHW; Ter Maaten, JM; Verbrugge, FH, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martens, P | 1 |
| Dauw, J | 1 |
| Verbrugge, FH | 1 |
| Nijst, P | 1 |
| Meekers, E | 1 |
| Augusto, SN | 1 |
| Ter Maaten, JM | 1 |
| Damman, K | 1 |
| Mebazaa, A | 1 |
| Filippatos, G | 1 |
| Ruschitzka, F | 1 |
| Tang, WHW | 1 |
| Dupont, M | 1 |
| Mullens, W | 1 |
| Mekontso Dessap, A | 1 |
| Roche-Campo, F | 1 |
| Kouatchet, A | 1 |
| Tomicic, V | 1 |
| Beduneau, G | 1 |
| Sonneville, R | 1 |
| Cabello, B | 1 |
| Jaber, S | 1 |
| Azoulay, E | 1 |
| Castanares-Zapatero, D | 1 |
| Devaquet, J | 1 |
| Lellouche, F | 1 |
| Katsahian, S | 1 |
| Brochard, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Weaning of Mechanical Ventilation Guided by the Natriuretic Peptide of Type B[NCT00473148] | Phase 3 | 265 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for acetazolamide and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.
Topics: Acetazolamide; Diuretics; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Sodium Po | 2023 |
Natriuretic peptide-driven fluid management during ventilator weaning: a randomized controlled trial.
Topics: Acetazolamide; Aged; Diuretics; Female; Furosemide; Humans; Male; Middle Aged; Natriuretic Peptide, | 2012 |